Benzinga··Vandana SinghNovartis Expands Cosentyx Reach Into Pediatric Dermatology With FDA Approval
Novartis wins FDA approval for Cosentyx in pediatric hidradenitis suppurativa patients aged 12+, marking the drug's fourth pediatric indication and expanding its dermatology portfolio.
NVSFDA approvalautoimmune disease